Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3995
Single User License Price INR 275655
Corporate User License Price USD 11985
Corporate User License Price INR 826965
Site License Price USD 7990
Site License Price INR 551310
Request a Quote

Report Title

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

Quote Request for License Type
License Type Price  
Single User License USD 3995
Site License USD 7990
Enterprise Wide License USD 11985
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Chronic Respiratory Disease Drug Development Pipeline Review, 2018


Quote Request for License Type
License Type Price  
Single User License USD 3995
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Chronic Respiratory Disease Drug Development Pipeline Review, 2018



Executive Summary

Chronic Respiratory Disease Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for chronic respiratory diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Asthma is a chronic disease involving the airways in the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, being overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. There are 275 products in development for this indication.

COPD is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs, leading to shortness of breath and blocked airflow to the lungs. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over time, increasing complications. The main risk factor is smoking. Exposure to chemicals and air pollution also contribute in the development of COPD. There are 187 products in development for this indication.

IPF is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. There are 136 products in development for this indication.

Molecular targets in development for chronic respiratory diseases include phosphodiesterases, adrenergic receptors, interleukins and chemokine receptors. Companies operating in this pipeline space include AstraZeneca, GlaxoSmithKline and Galapagos.

Scope

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 11

2 Introduction 12

2.1 Chronic Respiratory Disease Report Coverage 12

2.2 Asthma-Overview 12

2.3 Chronic Obstructive Pulmonary Disease (COPD)-Overview 12

2.4 Idiopathic Pulmonary Fibrosis-Overview 12

3 Therapeutics Development 13

3.1 Asthma 13

3.2 Chronic Obstructive Pulmonary Disease (COPD) 33

3.3 Idiopathic Pulmonary Fibrosis 51

4 Therapeutics Assessment 65

4.1 Asthma 65

4.2 Chronic Obstructive Pulmonary Disease (COPD) 81

4.3 Idiopathic Pulmonary Fibrosis 94

5 Companies Involved in Therapeutics Development 106

5.1 Asthma 106

5.2 Chronic Obstructive Pulmonary Disease (COPD) 172

5.3 Idiopathic Pulmonary Fibrosis 223

6 Dormant Projects 259

6.1 Asthma 259

6.2 Chronic Obstructive Pulmonary Disease (COPD) 279

6.3 Idiopathic Pulmonary Fibrosis 302

7 Discontinued Products 307

7.1 Asthma 307

7.2 Chronic Obstructive Pulmonary Disease (COPD) 311

7.3 Idiopathic Pulmonary Fibrosis 316

8 Product Development Milestones 317

8.1 Asthma 317

8.2 Chronic Obstructive Pulmonary Disease (COPD) 331

8.3 Idiopathic Pulmonary Fibrosis 345

9 Appendix 360

9.1 Methodology 360

9.2 Coverage 360

9.3 Secondary Research 360

9.4 Primary Research 360

9.5 Expert Panel Validation 360

9.6 Contact Us 360

9.7 Disclaimer 361

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

1.2 List of Figures

Figure 1: Number of Products under Development for Asthma 13

Figure 2: Number of Products under Development by Companies, Asthma 14

Figure 3: Number of Products under Development by Universities/Institutes, Asthma 19

Figure 4: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD 33

Figure 5: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34

Figure 6: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38

Figure 7: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51

Figure 8: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 52

Figure 9: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56

Figure 10: Number of Products by Top 10 Targets, Asthma 65

Figure 11: Number of Products by Stage and Top 10 Targets, Asthma 65

Figure 12: Number of Products by Top 10 Mechanism of Actions, Asthma 71

Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Asthma 71

Figure 14: Number of Products by Top 10 Routes of Administration, Asthma 76

Figure 15: Number of Products by Stage and Top 10 Routes of Administration, Asthma 77

Figure 16: Number of Products by Top 10 Molecule Types, Asthma 78

Figure 17: Number of Products by Stage and Top 10 Molecule Types, Asthma 79

Figure 18: Number of Products by Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81

Figure 19: Number of Products by Stage and Top 10 Targets, Chronic Obstructive Pulmonary Disease (COPD) 81

Figure 20: Number of Products by Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 85

Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Obstructive Pulmonary Disease (COPD) 86

Figure 22: Number of Products by Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91

Figure 23: Number of Products by Stage and Top 10 Routes of Administration, Chronic Obstructive Pulmonary Disease (COPD) 91

Figure 24: Number of Products by Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 92

Figure 25: Number of Products by Stage and Top 10 Molecule Types, Chronic Obstructive Pulmonary Disease (COPD) 93

Figure 26: Number of Products by Top 10 Targets, Idiopathic Pulmonary Fibrosis 94

Figure 27: Number of Products by Stage and Top 10 Targets, Idiopathic Pulmonary Fibrosis 94

Figure 28: Number of Products by Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 97

Figure 29: Number of Products by Stage and Top 10 Mechanism of Actions, Idiopathic Pulmonary Fibrosis 98

Figure 30: Number of Products by Routes of Administration, Idiopathic Pulmonary Fibrosis 102

Figure 31: Number of Products by Stage and Routes of Administration, Idiopathic Pulmonary Fibrosis 102

Figure 32: Number of Products by Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 103

Figure 33: Number of Products by Stage and Top 10 Molecule Types, Idiopathic Pulmonary Fibrosis 104

1.1 List of Tables

Table 1: Number of Products under Development for Asthma 13

Table 2: Number of Products under Development by Companies, Asthma 15

Table 3: Number of Products under Development by Universities/Institutes, Asthma 20

Table 4: Products under Development by Companies, Asthma 21

Table 5: Products under Development by Universities/Institutes, Asthma 31

Table 6: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) 33

Table 7: Number of Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 34

Table 8: Number of Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 38

Table 9: Products under Development by Companies, Chronic Obstructive Pulmonary Disease (COPD) 39

Table 10: Products under Development by Universities/Institutes, Chronic Obstructive Pulmonary Disease (COPD) 50

Table 11: Number of Products under Development for Idiopathic Pulmonary Fibrosis 51

Table 12: Number of Products under Development by Companies, Idiopathic Pulmonary Fibrosis 53

Table 13: Number of Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 56

Table 14: Products under Development by Companies, Idiopathic Pulmonary Fibrosis 57

Table 15: Products under Development by Universities/Institutes, Idiopathic Pulmonary Fibrosis 64

Table 16: Number of Products by Stage and Target, Asthma 66

Table 17: Number of Products by Stage and Mechanism of Action, Asthma 72

Table 18: Number of Products by Stage and Route of Administration, Asthma 78

Table 19: Number of Products by Stage and Molecule Type, Asthma 80

Table 20: Number of Products by Stage and Target, Chronic Obstructive Pulmonary Disease (COPD) 82

Table 21: Number of Products by Stage and Mechanism of Action, Chronic Obstructive Pulmonary Disease (COPD) 87

Table 22: Number of Products by Stage and Route of Administration, Chronic Obstructive Pulmonary Disease (COPD) 92

Table 23: Number of Products by Stage and Molecule Type, Chronic Obstructive Pulmonary Disease (COPD) 93

Table 24: Number of Products by Stage and Target, Idiopathic Pulmonary Fibrosis 95

Table 25: Number of Products by Stage and Mechanism of Action, Idiopathic Pulmonary Fibrosis 99

Table 26: Number of Products by Stage and Route of Administration, Idiopathic Pulmonary Fibrosis 103

Table 27: Number of Products by Stage and Molecule Type, Idiopathic Pulmonary Fibrosis 105

Table 28: Asthma-Pipeline by 4D Pharma PLC 106

Table 29: Asthma-Pipeline by AB Science SA 106

Table 30: Asthma-Pipeline by AbbVie Inc 107

Table 31: Asthma-Pipeline by Abeome Corp 107

Table 32: Asthma-Pipeline by Accolade Pharmaceuticals LLC 108

Table 33: Asthma-Pipeline by Adamis Pharmaceuticals Corp 108

Table 34: Asthma-Pipeline by ALK-Abello AS 109

Table 35: Asthma-Pipeline by Allergan Plc 110

Table 36: Asthma-Pipeline by Allergopharma GmbH & Co KG 111

Table 37: Asthma-Pipeline by Almirall SA 111

Table 38: Asthma-Pipeline by Amgen Inc 112

Table 39: Asthma-Pipeline by Amphastar Pharmaceuticals Inc 112

Table 40: Asthma-Pipeline by AnaptysBio Inc 113

Table 41: Asthma-Pipeline by AnGes Inc 113

Table 42: Asthma-Pipeline by Antisense Therapeutics Ltd 114

Table 43: Asthma-Pipeline by Apollo Endosurgery Inc 114

Table 44: Asthma-Pipeline by ASIT Biotech SA 115

Table 45: Asthma-Pipeline by Aslan Pharmaceuticals Pte Ltd 115

Table 46: Asthma-Pipeline by Astellas Pharma Inc 116

Table 47: Asthma-Pipeline by AstraZeneca Plc 117

Table 48: Asthma-Pipeline by Aurigene Discovery Technologies Ltd 117

Table 49: Asthma-Pipeline by Biocon Ltd 118

Table 50: Asthma-Pipeline by BiosanaPharma BV 118

Table 51: Asthma-Pipeline by Biotec Pharmacon ASA 119

Table 52: Asthma-Pipeline by Boehringer Ingelheim GmbH 119

Table 53: Asthma-Pipeline by Celon Pharma SA 120

Table 54: Asthma-Pipeline by Chiesi Farmaceutici SpA 121

Table 55: Asthma-Pipeline by Crossject SA 121

Table 56: Asthma-Pipeline by CrystalGenomics Inc 122

Table 57: Asthma-Pipeline by CSL Ltd 123

Table 58: Asthma-Pipeline by CSPC Pharmaceutical Group Limited 123

Table 59: Asthma-Pipeline by Cumberland Pharmaceuticals Inc 124

Table 60: Asthma-Pipeline by Cynata Therapeutics Ltd 124

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

4D Pharma PLC

AbbVie Inc

Accolade Pharmaceuticals LLC

Ache Laboratorios Farmaceuticos SA

AdAlta Ltd

Advanced Inhalation Therapies (AIT) Ltd

Aeolus Pharmaceuticals Inc

AlgiPharma AS

ALK-Abello AS

Allergan Plc

Allergopharma GmbH & Co KG

Allinaire Therapeutics LLC

Almirall SA

Amgen Inc

Amphastar Pharmaceuticals Inc

Amplia Therapeutics Ltd

AnaMar AB

AnaptysBio Inc

AnGes Inc

Angiocrine Bioscience Inc

Antisense Therapeutics Ltd

Apollo Endosurgery Inc

Aridis Pharmaceuticals Inc

Asahi Kasei Corp

ASIT Biotech SA

Aslan Pharmaceuticals Pte Ltd

Aurigene Discovery Technologies Ltd

AusBio Ltd

BerGenBio ASA

Biocon Ltd

Biogen Inc

BiosanaPharma BV

BioStem Technologies Inc

Biotec Pharmacon ASA

BreStem Therapeutics Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings PLC

Celdara Medical LLC

Celgene Corp

Certa Therapeutics Pty Ltd

China Resources Pharmaceutical Group Ltd

Chronic Obstructive Pulmonary Disease (COPD)

Cipla Ltd

Circassia Pharmaceuticals Plc

Compugen Ltd

Crossject SA

CrystalGenomics Inc

CSPC Pharmaceutical Group Limited

Cumberland Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Denceptor Therapeutics Ltd

Denovo Biopharma LLC

Diffusion Pharmaceuticals Inc

Domainex Ltd

Energenesis Biomedical Co Ltd

Errant Gene Therapeutics LLC

Evaxion Biotech ApS

FibroGen Inc

FibroStatin SL

FLX Bio Inc

Fountain Biopharma Inc

Galecto Biotech AB

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

GenKyoTex SA

Gilead Sciences Inc

Global Blood Therapeutics Inc

Gossamer Bio Inc

Grifols SA

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Humanigen Inc

Hydra Biosciences Inc

iBio Inc

iCo Therapeutics Inc

Idiopathic Pulmonary Fibrosis

Idorsia Pharmaceutical Ltd

InKemia IUCT Group SA

InMed Pharmaceuticals Inc

Insmed Inc

Inspyr Therapeutics Inc

Inventiva

Isarna Therapeutics GmbH

JHL Biotech Inc

Johnson & Johnson

Kadmon Corp LLC

Knopp Biosciences LLC

Kyorin Pharmaceutical Co Ltd

Laboratorios LETI SL

Lead Discovery Center GmbH

LG Chem Ltd

LifeMax Laboratories Inc

Longevity Biotech Inc

Lung Therapeutics Inc

Merck & Co Inc

Mereo Biopharma Group Plc

Meridigen Biotech Co Ltd

Miragen Therapeutics Inc

Mission Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Moerae Matrix Inc

Mycenax Biotech Inc

NAL Pharmaceuticals Ltd

NeoPharm Co Ltd

Novo Nordisk AS

Nuevolution AB

Nuformix Plc

Octapharma AG

OliX Pharmaceuticals Inc

Omeros Corp

OncBioMune Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Onspira Therapeutics Inc

Orbis Biosciences Inc

Oxagen Ltd

Paradigm Biopharmaceuticals Ltd

Paragen Bio Pty Ltd

PharmaLundensis AB

Pieris Pharmaceuticals Inc

Pliant Therapeutics Inc

Progenra Inc

Prommune Inc

Pulmagen Therapeutics LLP

Pulmokine Inc

Pulmotect Inc

Quark Pharmaceuticals Inc

Qurient Co Ltd

Redx Pharma Plc

Reliance Life Sciences Pvt Ltd

Resolys Bio Inc

Revalesio Corp

ReveraGen BioPharma Inc

Reviva Pharmaceuticals Inc

rEVO Biologics Inc

Rhizen Pharmaceuticals SA

Sam-A Pharm Co Ltd

Samumed LLC

SATT North SAS

Shionogi & Co Ltd

Sorrento Therapeutics Inc

Swecure AB

Synairgen Plc

Synermore Biologics Co Ltd

Synovo GmbH

Syntrix Biosystems Inc

Taiho Pharmaceutical Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

Telocyte LLC

Teva Pharmaceutical Industries Ltd

The Geneva Biotech Center SA

United BioPharma Inc

Unizyme Laboratories AS

Vascular BioSciences

Vectura Group Plc

Vicore Pharma AB

WhanIn Pharmaceutical Co Ltd

Xencor Inc

X-Rx Inc

Yuhan Corp

Yungjin Pharm Co Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person